TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22822019

Group type: EXPERIMENTAL
Intervention: Active spinal anesthesia with fentanyl (25 μg, intrathecal L(3)‐L(4))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham spinal anesthesia (NaCl, interspinous L(3)‐L(4))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active spinal anesthesia with fentanyl
Number of subjects: 8
Study: 20929127

Group type: EXPERIMENTAL
Intervention: Bushen Recipe (BSR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: alpha‐2b interferon
Number of subjects: 35
Study: 17803698

Group type: EXPERIMENTAL
Intervention: Pioglitazone, 30 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16142016

Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg x 2/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glimepiride (2 mg/day)
Number of subjects: 14
Study: 12374719

Group type: EXPERIMENTAL
Intervention: Cuff inflation at removal (Group A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cuff deflation at removal (Group B)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall comparison between Group A and Group B
Number of subjects: 126
Study: 10628600

Group type: EXPERIMENTAL
Intervention: Ethanol, 0.35-0.60 g/kg body weight intravenously, during 1 hr, repeated daily during the first week postburn
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control subjects received the same amount of ethanol once
Number of subjects: 17
Study: 7745515

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 957

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 957
Study: 2289995

Group type: EXPERIMENTAL
Intervention: Selective decontamination (SD) medication, administered preoperatively
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional prophylaxis
Number of subjects: 114
Study: 394563

Group type: EXPERIMENTAL
Intervention: Oral bromocriptine (5 mg dd for 14 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral stilbestrol (15 mg dd for 5 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diuretic compound (bendroflumethazide 15 mg dd for 5 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of estradiol (10 mg) and testosterone (200 mg) esters administered immediately after delivery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical methods (breast support and local infra-red waves)
Number of subjects: 90
Study: 31791393

Group type: EXPERIMENTAL
Intervention: Subscription journals
Number of subjects: 268

Group type: COMPARATOR
Intervention: Open access journals
Number of subjects: 268
Study: 27682207

Group type: EXPERIMENTAL
Intervention: Pain self-management program (PSM)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Exercise-attention control (EAC)
Number of subjects: 141
Study: 25853511

Group type: EXPERIMENTAL
Intervention: MCH handbook implementation
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (no MCH handbook)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: MCH handbook usage
Number of subjects: 501
Study: 23421781

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Amoxycillin-clavulanate (22.5 mg/kg twice daily)
Number of subjects: 170
Study: 21878810

Group type: EXPERIMENTAL
Intervention: Intravenous treatment with ketamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous treatment with morphine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with neuropathic pain
Number of subjects: 10
Study: 19669886

Group type: EXPERIMENTAL
Intervention: Computeen program (preventive technology and psychosocial skills development)
Number of subjects: 55
Study: 17848673

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15549976

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 20
Study: 11905957

Group type: EXPERIMENTAL
Intervention: Corn oil diet (80 g corn oil/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mixed oil diet (68 g olive oil and 12 g sunflower oil/d)
Number of subjects: 28
Study: 9591764

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3171
Study: 8176569

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 80
Study: 3067654

Group type: EXPERIMENTAL
Intervention: 7.5 mg bromocriptine at bedtime
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29663320

Group type: EXPERIMENTAL
Intervention: Direct-to-implant breast reconstruction with acellular dermal matrix (ADM)
Number of subjects: 59
Study: 28068857

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo + standard of care (SOC)
Number of subjects: 241
Study: 26486928

Group type: EXPERIMENTAL
Intervention: metoclopramide combined with diphenhydramine
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: metoclopramide combined with diphenhydramine and dexamethasone
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: metoclopramide alone
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: valproate
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Any medication regimen
Number of subjects: 884
Study: 24125149

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 14
Study: 19939587

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride (SEL, 5mg bid, n=51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (PLO, n=50)
Number of subjects: 101
Study: 18591906

Group type: EXPERIMENTAL
Intervention: Acupuncture (manual and electroacupuncture)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Acupuncture (manual and electroacupuncture) and Non-penetrating sham acupuncture
Number of subjects: 68
Study: 16909787

Group type: EXPERIMENTAL
Intervention: Treatment for TBE meningitis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treatment for neuroborreliosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 14659772

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0
Study: 10966942

Group type: EXPERIMENTAL
Intervention: National Eye Care Programme (NECP) interventions
Number of subjects: 1169000
Study: 8792380

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1482871

Group type: EXPERIMENTAL
Intervention: Computer-assisted interventions (various types including reminder, feedback, dose planning, patient education, medical record)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 106
Study: 4036844

Group type: EXPERIMENTAL
Intervention: minimal-carbohydrate diet (800 kcal; 58% protein and 42% fat by weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: carbohydrate-supplemented diet (1,000 kcal; 42% protein, 30% fat, and 28% carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: minimal-carbohydrate diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: carbohydrate-supplemented diet
Number of subjects: 20
Study: 31248950

Group type: EXPERIMENTAL
Intervention: Esaxerenone 1.25 mg/d
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/d
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/d
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 28586239

Group type: EXPERIMENTAL
Intervention: kiR urban version of the curriculum
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: kiR rural version of the curriculum
Number of subjects: 1464
Study: 27115376

Group type: EXPERIMENTAL
Intervention: 6 SQ‐HDM
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: 12 SQ‐HDM
Number of subjects: 834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study: 24502414

Group type: EXPERIMENTAL
Intervention: customary treatment plus active physiotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: customary treatment (information and advice on a specialist clinic)
Number of subjects: 200
Study: 22191494

Group type: EXPERIMENTAL
Intervention: Nephrostomy tract infiltration with bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 60
Study: 21058474

Group type: EXPERIMENTAL
Intervention: Acupuncture and medication (Thiamazole and Euthyrox)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 52
Study: 17652834

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 16188135

Group type: EXPERIMENTAL
Intervention: sapylin + cisplatin (DDP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: cisplatin alone (DDP)
Number of subjects: 60
Study: 12422105

Group type: EXPERIMENTAL
Intervention: Thigh-length sequential EPC devices (EPC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous heparin injections (HEP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both (HEP+EPC)
Number of subjects: 45
Study: 10600289

Group type: EXPERIMENTAL
Intervention: Cold knife excision (n = 38)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Loop excision (n = 28)
Number of subjects: 66
Study: 8949824

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg and dimethindene 0.1 mg kg‐1 (H1 blocker)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2038996

Group type: EXPERIMENTAL
Intervention: Naproxen (1000 mg daily for 7 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Aspirin (3900 mg daily for 7 days)
Number of subjects: 61
Study: 6215443

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorimipramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drug groups
Number of subjects: 30
Study: 30796199

Group type: EXPERIMENTAL
Intervention: Carfilzomib-dexamethasone (Kd56)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Bortezomib-dexamethasone (Vd)
Number of subjects: 911
Study: 29420600

Group type: EXPERIMENTAL
Intervention: +50% precipitation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +33% precipitation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: -50% precipitation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: -33% precipitation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient precipitation treatment
Number of subjects: 0
Study: 27044272

Group type: EXPERIMENTAL
Intervention: Compliant flooring (2.54 cm SmartCells)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control flooring (2.54 cm plywood)
Number of subjects: 150
Study: 25244777

Group type: EXPERIMENTAL
Intervention: Ganfule prescription combined with chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 58
Study: 22307494

Group type: EXPERIMENTAL
Intervention: Oral essential amino acids (EAAs) 8 g/d for 2 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 19358074

Group type: EXPERIMENTAL
Intervention: Back School integrated into a multidisciplinary programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Back School
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Back School in an occupational setting
Number of subjects: 0
Study: 17197463

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 2.5 mg with fentanyl 15 microg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Plain bupivacaine 2.5 mg with fentanyl 15 microg
Number of subjects: 62
Study: 15502419

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.75%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine (2%)
Number of subjects: 50
Study: 11470620

Group type: EXPERIMENTAL
Intervention: Video-consultation (Mode C)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Teleradiology and telephone consultation (Mode B)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Telephone consultation only (Mode A)
Number of subjects: 327
Study: 9895184

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine to invigorate blood and relieve stasis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antipsychotic drugs
Number of subjects: 80
Study: 8023144

Group type: EXPERIMENTAL
Intervention: Thermal grill illusion (interlaced warm and cool bars)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurophysiological recordings from ascending spinothalamic tract neurons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysical verification of the model
Number of subjects: 0
Study: 2557268

Group type: EXPERIMENTAL
Intervention: Beta-blocker atenolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cold water stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warm water stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Beta blockade
Number of subjects: 9
Study: 31228629

Group type: EXPERIMENTAL
Intervention: Auvi-Q
Number of subjects: 96

Group type: COMPARATOR
Intervention: EpiPen Jr
Number of subjects: 96
Study: 28706262

Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 g/l of body water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study: 26495912

Group type: COMPARATOR
Intervention: Tadalafil only
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Combination of Tadalafil + Pentoxifylline
Number of subjects: 237
Study: 22929394

Group type: EXPERIMENTAL
Intervention: Exercise-training group (3 times a week for 12 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 83
Study: 22128614

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids 2 g/day for at least 5 days before surgery and until hospital discharge
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no n‐3 polyunsaturated fatty acids)
Number of subjects: 201
Study: 18384467

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 195
Study: 17211567

Group type: EXPERIMENTAL
Intervention: Combination of multiple insulin injections and oral repaglinide (1.5 mgr tid)
Number of subjects: 50
Study: 12798824

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11420773

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol‐17 beta with cyclical dydrogesterone
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol‐17 beta with cyclical dydrogesterone
Number of subjects: 595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study: 9263561

Group type: EXPERIMENTAL
Intervention: Varicella infection during the first 20 weeks of gestation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Infants of women with varicella
Number of subjects: 22
Study: 8325066

Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (12 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (24 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (48 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10
Study: 3792214

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neomycin (all subjects simultaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31864157

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) for ≤ 4 cycles (group 1)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) for ≥ 5 cycles (group 2)
Number of subjects: 501
Study: 29802652

Group type: EXPERIMENTAL
Intervention: Help-seeking from health professionals
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Informational support
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Help-seeking from general practitioners
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Help-seeking from oncologist/treating clinician
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Identification as a lung cancer patient
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Perceived legitimacy of discrimination
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Help-seeking behaviours
Number of subjects: 274
Study: 27991894

Group type: EXPERIMENTAL
Intervention: PK-guided IV busulfan (AUC of 6000 μM min)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Fixed-dose IV busulfan (130 mg/m2)
Number of subjects: 218
Study: 25800362

Group type: EXPERIMENTAL
Intervention: Attentional bias modification
Number of subjects: 43

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 43
Study: 23887998

Group type: EXPERIMENTAL
Intervention: Mentalisation-based treatment (MBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured clinical management (SCM)
Number of subjects: 0
Study: 21940527

Group type: EXPERIMENTAL
Intervention: PRECISION TACE with drug-eluting beads (DEB)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 212
Study: 18177513

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16456680

Group type: EXPERIMENTAL
Intervention: G+MET (insulin glargine + metformin)
Number of subjects: 110

Group type: COMPARATOR
Intervention: NPH+MET (NPH insulin + metformin)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: G+MET
Number of subjects: 110

Group type: COMPARATOR
Intervention: NPH+MET
Number of subjects: 110
Study: 15023878

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice per week (RENAISSANCE)
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (RECOVER)
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Etanercept (combined higher doses)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Placebo (RENAISSANCE)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Placebo (RECOVER)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Placebo (combined higher doses)
Number of subjects: 2078
Study: 11477530

Group type: EXPERIMENTAL
Intervention: Norwalk-like virus infection
Number of subjects: 775
Study: 9286464

Group type: EXPERIMENTAL
Intervention: Highly oleic sunflower oil (HOSO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Palmolein
Number of subjects: 42
Study: 8360240

Group type: EXPERIMENTAL
Intervention: Unna Boot applied every 7 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional dressing and antihistamines
Number of subjects: 6
Study: 3096364

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fentanyl and Alfentanil (comparison)
Number of subjects: 19
Study: 29742652

Group type: EXPERIMENTAL
Intervention: Honeycomb technique with Cavitron Ultrasonic Surgical Aspirator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microdissection technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Honeycomb technique
Number of subjects: 40
Study: 27212181

Group type: EXPERIMENTAL
Intervention: Boswellia, betaine, myo-inositol, B-group vitamins, N-acetylcysteine
Number of subjects: 64

Group type: COMPARATOR
Intervention: B-group vitamins, N-acetylcysteine (placebo)
Number of subjects: 64
Study: 24845963

Group type: EXPERIMENTAL
Intervention: Elevated MELD‐XI scores (≥16.8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal liver function tests (LFTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated total bilirubin
Number of subjects: 0
Study: 22748747

Group type: EXPERIMENTAL
Intervention: FOR + TIO (Formoterol 12 μg twice a day + Tiotropium 18 μg once a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: FOR + PLA (Formoterol 12 μg twice a day + Placebo)
Number of subjects: 38
Study: 20002779

Group type: EXPERIMENTAL
Intervention: 0.7 mg/day rhGH for 40 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17573509

Group type: EXPERIMENTAL
Intervention: Simulator training (deliberate practice of ACLS scenarios using a human patient simulator)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional ACLS education (no simulator training)
Number of subjects: 2
Study: 11432696

Group type: EXPERIMENTAL
Intervention: Citalopram 5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg with Cyproheptadine (4 mg)
Number of subjects: 17
Study: 9466036

Group type: EXPERIMENTAL
Intervention: Tetracaine in glucose 10%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tetracaine in NaCl 5%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tetracaine in glucose 5%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tetracaine in NaCl 2.5%
Number of subjects: 42
Study: 7949021

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BC) treatment
Number of subjects: 37
Study: 3282479

Group type: EXPERIMENTAL
Intervention: Alprazolam (2 to 10 mg daily for eight weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 31032364

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS)
Number of subjects: 6713

Group type: EXPERIMENTAL
Intervention: Nomogram for cancer-specific survival (CSS)
Number of subjects: 6713
Study: 28084515

Group type: EXPERIMENTAL
Intervention: Forsus fatigue resistant device (FRD) with fixed appliances
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pendulum appliance combined with Nance and headgear followed by fixed appliances
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extraction of two maxillary premolars with miniscrew anchorage
Number of subjects: 54
Study: 25131305

Group type: EXPERIMENTAL
Intervention: Turmeric
Number of subjects: 50